dolutegravir

ViiV goes for gold: US premium pricing may threaten dolutegravir use in Europe

Leave a Comment / Blogger, Uncategorized /

On 12 August 2013, the FDA approved dolutegravir in the US. i-Base reported the news with an article linked to previous clinical trial results that noted not only the potential advantages but also some of the cautions.  One of the concerns was how the price, which didn’t accompany the original company press statement, would be […]

ViiV goes for gold: US premium pricing may threaten dolutegravir use in Europe Read More »

Report from CROI-2013- My Personal Picks

Leave a Comment / Blogger, Uncategorized /

CROI 2013 Report Nelson Vergel I was happy to attend  CROI-2013 in Atlanta on March 3-6, 2013.  These are areas of great interest to me and in no way attempts to summarize the main findings reported at the conference.  For abstract information, refer to https://www.retroconference.org/AbstractSearch/default2.aspx?conf=22 A baby girl gets cured   The most popular media

Report from CROI-2013- My Personal Picks Read More »

New HIV Drugs and Formulations in the Near Future (CROI 2013 Presentation)

Leave a Comment / Blogger, Uncategorized /

All of the presentations in this section were great. The one on new drugs is contained in the last set of slides (blue slides at 1:22:46) https://webcasts.retroconference.org/console/player/19437?mediaType=podiumVideo For individual reports on each drug (Thanks to Natap.org): NEW HIV DRUGS at CROI Dolutegravir Treatment Response and Safety by Key Subgroups in Treatment Naive HIV Infected Individuals – (03/16/13) Dolutegravir (DTG)

New HIV Drugs and Formulations in the Near Future (CROI 2013 Presentation) Read More »

WORLD AIDS DAY: Time to Help Victims of HIV Drug Studies and Resistance

Leave a Comment / Blogger, Uncategorized /

We have repeatedly heard the following statements about multi-drug resistant HIV (MDR-HIV) patients in a host of meetings on treatment access and HIV research: “These patients no longer exist – they’re either dead or have responded to the latest ARVs”; “Only patients who do not adhere to their HIV regimens have MDR-HIV”; and “Our clinic cannot provide expanded access programs (EAPs) due

WORLD AIDS DAY: Time to Help Victims of HIV Drug Studies and Resistance Read More »

Ten News Items That Have Made Me Happy During the Past Month

Leave a Comment / Blogger, Uncategorized /

These past several weeks have been great on many fronts. While taking a shower this morning, I counted a few of the great pieces of news that have come our way amidst all the negative news that the media dwells on to increase ratings.  https://www.thebody.com/content/67329/ten-news-items-that-have-made-me-happy-during-the.html

Ten News Items That Have Made Me Happy During the Past Month Read More »

Shionogi-ViiV Healthcare announces initial data from pivotal phase III study of dolutegravir in HIV

Leave a Comment / Blogger, Uncategorized /

This drug will compete against raltegravir (Merck) and elvitegravir (Gilead).  It will be dosed once a day for treatment naive patients and twice a day for treatment experienced. Issued: Monday 02 April 2012, London, UK Press release issued by Shionogi-ViiV Healthcare LLC, a joint venture between ViiV Healthcare Ltd (a global specialist HIV company established

Shionogi-ViiV Healthcare announces initial data from pivotal phase III study of dolutegravir in HIV Read More »

ViiV Announces Expanded Access of New Integrase Inhibitor…But Activists Are Concerned About Its Potential Misuse

Leave a Comment / Blogger, Uncategorized /

The dolutegravir expanded access program (EAP) has been designed to provide free access to Shionogi-ViiV Healthcare’s investigational integrase inhibitor, dolutegravir (DTG, S/GSK1349572) in an open-label protocol program to adults living with HIV who have documented raltegravir or elvitegravir resistance, who have limited treatment options, and who require DTG to construct a viable antiretroviral regimen for

ViiV Announces Expanded Access of New Integrase Inhibitor…But Activists Are Concerned About Its Potential Misuse Read More »

Activists Caution HIV+ Patients and their Physicians About Monotherapy in Upcoming Access Program

Leave a Comment / Blogger, Uncategorized /

FOR IMMEDIATE RELEASE: February 9, 2012 Contact: Nelson Vergel ([email protected]) Activists Caution HIV+ Patients and their Physicians About Monotherapy in Upcoming Access Program New York, February 9, 2012—AIDS activists and physician advocates welcome the news that ViiV Healthcare will be providing  expanded access of dolutegravir (DTG), a new investigational integrase inhibitor for HIV patients with

Activists Caution HIV+ Patients and their Physicians About Monotherapy in Upcoming Access Program Read More »

For Doctors: How You Can Help Your Patients Who Are Running Out of HIV Treatment Options

Leave a Comment / Blogger, Uncategorized /

By Nelson Vergel, B.S.Ch.E., M.B.A. July 6, 2011 In a previous blog post, I reviewed the current situation for the minority of patients with HIV who have run out of treatment options. Of the HIV medications in development with potential activity against highly resistant HIV (i.e., patients with GSS=0), two may become available within the next

For Doctors: How You Can Help Your Patients Who Are Running Out of HIV Treatment Options Read More »

GSK- ViiV start their phase 3 study for their second generation integrase inhibitor (dolutegravir) in raltegravir experienced patients

Leave a Comment / Blogger, Uncategorized /

https://clinicaltrials.gov/ct2/show/NCT01328041?term=dolutegravir&rank=1 For more on dolutegravir: Report from CROI 2011 Dr Joe Eron presented new dosing and efficacy phase 2b data on the new GSK integrase inhibitor dolutegravir (DTG, S/GSK1349572) using 50 mg twice a day in patients whose HIV virus has developed resistance to raltegravir (Isentress). Prior data presented in Vienna from a cohort (cohort

GSK- ViiV start their phase 3 study for their second generation integrase inhibitor (dolutegravir) in raltegravir experienced patients Read More »

Dolutegravir, Trii and new abacavir data- How it all ties together

Leave a Comment / Blogger, Uncategorized /

By Nelson Vergel Powerusa.org Dr Joe Eron presented new dosing and efficacy phase 2b data on the new GSK integrase inhibitor dolutegravir (DTG, S/GSK1349572) using 50 mg twice a day in patients whose HIV virus has developed resistance to raltegravir (Isentress). Prior data presented in Vienna from a cohort (cohort 1) of patients who took

Dolutegravir, Trii and new abacavir data- How it all ties together Read More »